United States Food and Drug Administration (USFDA) has concluded inspection at Lupin’s manufacturing facility located in Somerset, New Jersey, U.S.A. The inspection was conducted from April 13, 2026 to April 17, 2026 and closed with the issuance of a Form-483 with three observations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
